Invention Grant
- Patent Title: Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors
-
Application No.: US16315674Application Date: 2017-07-06
-
Publication No.: US10730858B2Publication Date: 2020-08-04
- Inventor: Zilun Hu , Cailan Wang , Mimi L. Quan , Peter W. Glunz
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Hong Liu
- International Application: PCT/US2017/040846 WO 20170706
- International Announcement: WO2018/009622 WO 20180111
- Main IPC: C07D403/10
- IPC: C07D403/10 ; C07D403/14 ; C07D405/14 ; C07D487/04 ; C07D495/04 ; C07D401/14 ; C07D413/10 ; C07D413/14 ; C07D417/14 ; C07D401/10
Abstract:
The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
Public/Granted literature
- US20190300510A1 LACTAM, CYCLIC UREA AND CARBAMATE, AND TRIAZOLONE DERIVATIVES AS POTENT AND SELECTIVE ROCK INHIBITORS Public/Granted day:2019-10-03
Information query
